Statin-associated muscular and renal adverse events: Data mining of the public version of the FDA adverse event reporting system

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Sakaeda, Toshiyuki ^a   Kadoyama, Kaori ^a   Okuno, Yasushi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE KIDNEY FAILURE; ARTIFICIAL NEURAL NETWORK; ASTHENIA; BAYES THEOREM; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DATA ANALYSIS; DATA MINING; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY FAILURE; LEG PAIN; MUSCLE DISEASE; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NEPHROTOXICITY; NON ACUTE RENAL FAILURE; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SIGNAL DETECTION; THORAX PAIN; ACCESS TO INFORMATION; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; KIDNEY; MALE; METHODOLOGY; MUSCLE; STATISTICS; UNITED STATES;

ACCESS TO INFORMATION; ADVERSE DRUG REACTION REPORTING SYSTEMS; CREATININE; DATA MINING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MALE; MUSCLES; RENAL INSUFFICIENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 83755196415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028124     Document Type: Review

References (36)

1. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, et al. (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1: CD004816.
2. Toth PP, (2010) Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs 70: 1363-1379.
3. Harper CR, Jacobson TA, (2010) Evidence-based management of statin myopathy. Curr Atheroscler Rep 12: 322-330.
4. Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA, (2010) Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther 90: 1530-1542.
5. Lardizabal JA, Deedwania PC, (2010) Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag 6: 843-853.
6. Weng TC, Yang YH, Lin SJ, Tai SH, (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35: 139-151.
7. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ, (2010) Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105: 69-76.
8. Editorial (2003) The statin wars: why AstraZeneca must retreat. Lancet 362: 1341.
9. McKillop T, (2003) The statin wars. Lancet 362: 1498.
10. Wolfe SM, (2004) Dangers of rosuvastatin identified before and after FDA approval. Lancet 363: 2189-2190.
11. Olsson GO, (2004) Safety and efficacy of rosuvastatin. Lancet 364: 135.
12. Florentinus SR, Heerdink ER, Klungel OH, de Boer A, (2004) Should rosuvastatin be withdrawn from the market? Lancet 364: 1577.
13. Kastelein JJ, (2004) Should rosuvastatin be withdrawn from the market? Lancet 364: 1578-9.
14. Cohen JS, (2004) Should rosuvastatin be withdrawn from the market? Lancet 364: 1579.
15. Meyboom RH, Edwards IR, (2004) Rosuvastatin and the statin wars-the way to peace. Lancet 364: 1997-1999.
16. Okie S, (2005) Safety in numbers-monitoring risk in approved drugs. N Engl J Med 352: 1173-1176.
17. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH, (2005) The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111: 3051-3057.
18. Zipes DP, Zvaifler NJ, Glassock RJ, Gilman S, Muñoz A, et al. (2006) Rosuvastatin: an independent analysis of risks and benefits. Med Gen Med 8: 73.
19. Evans SJ, Waller PC, Davis S, (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10: 483-486.
20. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, et al. (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11: 3-10.
21. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, et al. (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54: 315-321.
22. Szarfman A, Machado SG, O'Neill RT, (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 25: 381-392.
23. Bate A, Evans SJ, (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18: 427-436.
24. Gould AL, (2003) Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 12: 559-574.
25. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, et al. (2007) Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 82: 157-166.
26. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B, (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 19: 403-414.
27. Fernandez G, Spatz ES, Jablecki C, Phillips PS, (2011) Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 78: 393-403.
28. Dirks AJ, Jones KM, (2006) Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 291: C1208-1212.
29. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE, (2007) Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 30: 669-675.
30. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, et al. (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57: 728-734.
31. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, et al. (2007) Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2: 1131-1139.
32. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al. (2009) Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 54: 810-819.
33. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, et al. (2009) Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 53: 741-750.
34. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, et al. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106: 1024-1028.
35. Tomlinson SS, Mangione KK, (2005) Potential adverse effects of statins on muscle. Phys Ther 85: 459-465.
36. Oskarsson B, (2011) Myopathy: five new things. Neurology 76: S14-19.